⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLS News
SELLAS Life Sciences Group, Inc. Common Stock
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
globenewswire.com
ONCY
SLS
CELC
RNXT
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
globenewswire.com
SLS
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
globenewswire.com
GTBP
LYEL
CRBU
SLS
NRIX
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
globenewswire.com
SLS
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
prnewswire.com
GTBP
GERN
KURA
SLS
TCRX
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
SLS
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
globenewswire.com
SLS
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
globenewswire.com
SLS
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
globenewswire.com
SLS
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
globenewswire.com
SLS